65,437 trials
Erectile Dysfunction
Primary: Change From Baseline Between Tadalafil Once a Day (OaD) and Sildenafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship…
Migraine
Primary: Incidence of Fasting-induced Headache of Any Intensity — 12; 18 participants — p=0.172
Depressive Disorder, Major
Primary: 21-item Hamilton Depression Rating Scale Score (HAM-D) — 13.5; 15.6 units on a scale — p=0.71
Benign Prostatic Hyperplasia
Primary: Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) — -5.6; -3.6 Units on a Scale — p=0.004
Upper Respiratory Tract Infections
Primary: Maximal Level of Tumor Necrosis Factor Alpha (pg/ml) — 2694; 2648 tumor necrosis alpha level (pg/ml) — p=.17
Major Orthopaedic Surgery and Renal Impairment
Primary: Number of Patients With Major Bleedings Between Day 1 and Day 10. — 20 participants
Acne Vulgaris
Primary: Number of Inflammatory Lesions (Papules and Pustules) — 6; 3; 10; 0 Lesions
Astigmatism
Primary: Overall Vision — 8.2; 8.3 Units on a Scale
Acute Myelogenous Leukemia · Acute Lymphocytic Leukemia · Chronic Myelogenous Leukemia
Primary: Percent of Participants With Chimerism: Full Donor Chimerism Defined as >95% Donor CD3+ Cell in Blood as Assessed by DNA Fingerprinting — 85; 90 percent of participants
Infections, Rotavirus · Rotavirus Vaccines
Primary: Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains — 14; 34 subjects
Vaccines, Pneumococcal Conjugate Vaccine
Primary: Number of Participants With Spontaneous Adverse Events — 91 Participants
Respiratory Failure
Primary: Neuroventilatory Efficiency (NVE) — 17.6; 39.9 ml/uV — p=<0.05
Arthritis, Psoriatic
Primary: Number of Participants With Spontaneous Adverse Events Reported Until 30 Days After Each Injection — 7 Participants
Body Dysmorphic Disorder
Primary: Number of Responders on the Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS) — 9 Participants
Healthy
Primary: Cmax of Anastrozole(Maximum Observed Concentration of Drug Substance in Plasma) — 14.1; 14.2 ng/mL